KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
KalVista Pharmaceuticals, Inc. (KALV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$29.20 | $39.00 | $20.00 | 89.73% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for KalVista Pharmaceuticals, Inc. comes to $29.20. The forecasts range from a low of $20.00 to a high of $39.00. The average price target represents an increase of 89.73% from the last closing price of $15.39.
Analyst Price Targets (5 )
Broker Rating
KalVista Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.17 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.17 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 16.67% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
7/12/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
7/11/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
5/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/15/2023 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.17 |
ABR (Last week) | 1.17 |
# of Recs in ABR | 6 |
Average Target Price | $29.20 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | -0.93 |